Key Highlights of ParaZero’s Achievements in 2025 & Recent Highlights:
- Sales increased by 12.3% to
$1,046,644 for the year endedDecember 31, 2025 , primarily driven by newly developed products in the defense sector - Three purchase orders received from Israeli defense entities for DefendAir Counter-Unmanned Aerial Systems solutions reinforcing trust and operational reliance on ParaZero’s DefendAir platform.
- Cash position strengthened with registered direct offerings in 2026 yielding approximately
$7.5 million in gross proceeds.
Commercial and Regulatory Milestones
- In
January 2025 ,ParaZero announced that it received official approval from theIsraeli Defense Export Controls Agency (DECA) under theIsrael Ministry of Defense for the marketing of the DefendAir counter-UAS (C-UAS) solution. - In
April 2025 ,ParaZero received a marketing approval from DECA for the DropAir™ Precision Airdrop System, developed in collaboration with Heven Drones, a leadingU.S. drone manufacturer with roots inIsrael that specializes in custom autonomous UAS platforms. - In
October 2025 ,ParaZero announced the signing of a significant purchase order withAirobotics Ltd. (an Ondas company), a premier provider of robotic automation solutions, for the delivery of the company’s advanced safety systems. - In
November 2025 ,ParaZero received a significant purchase order for its DefendAir anti-drone defense systems from a Dutch distributor, one of Europe’s largest integrators that serves as a leading supplier of defense andhomeland security applications. - In
December 2025 ,ParaZero signed a distribution agreement with a leading Western European distributor specializing in advanced defense systems and force training solutions, which grants the distributor exclusive rights to distribute the DefendAir C-UAS across multiple Western European countries. - In
January 2026 ,ParaZero announced the receipt of the first purchase order from a main Israeli defense entity for the DefendAir solution. - In
February 2026 ,ParaZero announced the receipt of an additional order from a second branch at an Israeli defense entity for the DefendAir solution. The order included:- Specialized Launchers: High-precision net-launchers designed for rapid deployment in urban and field environments, enabling soft-kill interception of hostile drones with minimal collateral damage.
- Interception Pods: net-pods compatible with handheld, stationary, and drone-mounted configurations, providing layered defense for troops, convoys, and critical infrastructure.
- Training Package: A comprehensive suite of simulation-based and live-fire training modules to ensure operational readiness, including system integration, maintenance, and tactical deployment scenarios.
- In
March 2026 ,ParaZero announced the receipt of a new purchase order from an Israeli defense entity for the DefendAir solution. The order included the delivery of an evaluation kit including DefendAir’s net pods live exercise and training to support rapid operational deployment and maximize readiness. - In
March 2026 ,ParaZero signed a strategic cooperation agreement with BonV Aero, a leading Indian aerospace and defense technologies manufacturer, under which BonV Aero will market the DefendAir C-UAS solutions inIndia , following a successful live demonstration to a key Indian security entity.
Full Year 2025 Financial Highlights:
- Sales increased by 12.3%, to
$1,046,664 for the year endedDecember 31, 2025 , compared to$932,154 for the year endedDecember 31, 2024 . This increase was mainly attributed to the company shifting towards sales of newly developed products, mainly in the defense sector, and original equipment manufacturer integrations that contributed to a higher volume of sales. - Cost of sales increased by 14.1%, to
$996,701 for the year endedDecember 31, 2025 , compared to$873,861 for the year endedDecember 31, 2024 . The increase was mainly due to the increase of an inventory write-off of$194,344 during the year endedDecember 31, 2025 . - Research and development expenses increased by 9.1%, to
$2,338,221 for the year endedDecember 31, 2025 , compared to$2,143,353 for the year endedDecember 31, 2024 . The increase resulted mainly from labor costs due to the increased number of employees and consultants’ costs. - Sales and marketing expenses increased by 49.7%, to
$1,618,187 for the year endedDecember 31, 2025 , compared to$1,081,003 for the year endedDecember 31, 2024 . The increase resulted mainly from labor costs, marketing and promotion services and travel and conferences participation costs. - General and administrative expenses increased by 51.7%, to
$3,640,967 for the year endedDecember 31, 2025 , compared to$2,400,000 for the year endedDecember 31, 2024 . The increase resulted mainly from non-cash expenses of$1,086,247 related to grants pursuant to our equity incentive plan. - Net loss and comprehensive loss decreased by 51%, to
$5,412,163 for the year endedDecember 31, 2025 , compared to a net loss of$11,054,230 for the year endedDecember 31, 2024 . The decrease was the result of changes in fair value of derivative warrant liabilities, set off by an increase in expenses related to grants pursuant to our equity incentive plan along with an increase of operating expenses, as described above. - The loss per share for the year ended
December 31, 2025 , was$0.31 compared to loss per share of$0.99 for the year endedDecember 31, 2024 . - As of
December 31, 2025 , the company’s cash, cash equivalents, and short-term deposits was approximately$4.2 million .
A copy of ParaZero’s annual report on Form 20-F for the year ended
About ParaZero Technologies
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s Annual Report on Form 20-F filed with the
Investor Relations Contact:
Investor Relations
michal@efraty.com
BALANCE SHEETS (US dollars) | ||||||
| Note | 2025 | 2024 | ||||
| ASSETS | ||||||
| CURRENT ASSETS: | ||||||
| Cash and cash equivalents | 2,159,313 | 4,178,866 | ||||
| Short term deposits | 2,000,000 | — | ||||
| Trade receivables | 185,494 | 114,564 | ||||
| Other current assets | 3 | 283,010 | 421,919 | |||
| Inventories | 5 | 204,480 | 394,193 | |||
| TOTAL CURRENT ASSETS | 4,832,297 | 5,109,542 | ||||
| NON-CURRENT ASSETS: | ||||||
| Restricted deposit | 2Z | 80,721 | 68,001 | |||
| Prepaid expenses | 12,153 | 33,333 | ||||
| Operating lease right-of-use asset | 6 | 273,925 | 418,790 | |||
| Property and equipment, net | 7 | 106,224 | 107,906 | |||
| TOTAL NON-CURRENT ASSETS | 473,023 | 628,030 | ||||
| TOTAL ASSETS | 5,305,320 | 5,737,572 | ||||
BALANCE SHEETS (US dollars) | |||||||
| Note | 2025 | 2024 | |||||
| LIABILITIES AND SHAREHOLDERS’ EQUITY (DEFICIT) | |||||||
| CURRENT LIABILITIES: | |||||||
| Trade payables | 116,491 | 184,247 | |||||
| Operating lease liabilities | 6 | 245,682 | 202,563 | ||||
| Other current liabilities | 9 | 966,612 | 933,995 | ||||
| TOTAL CURRENT LIABILITIES | 1,328,785 | 1,320,805 | |||||
| NON-CURRENT LIABILITIES: | |||||||
| Derivative warrant liabilities | 13A | 758,872 | 4,511,491 | ||||
| Operating lease liabilities, net of current portion | 61,002 | 216,917 | |||||
| TOTAL NON-CURRENT LIABILITIES | 819,874 | 4,728,408 | |||||
| SHAREHOLDERS’ EQUITY (DEFICIT): | |||||||
| Ordinary shares, | 10 | 111,163 | 72,061 | ||||
| Additional paid-in capital | 37,934,948 | 29,093,585 | |||||
| Accumulated losses | (34,889,450 | ) | (29,477,287 | ) | |||
| TOTAL SHAREHOLDERS’ EQUITY (DEFICIT) | 3,156,661 | (311,641 | ) | ||||
| TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY (DEFICIT) | 5,305,320 | 5,737,572 | |||||
STATEMENTS OF COMPREHENSIVE LOSS (US dollars) | |||||||||||
| Year ended December 31, | |||||||||||
| Note | 2025 | 2024 | 2023 | ||||||||
| Sales | 11 | 1,046,664 | 932,154 | 620,508 | |||||||
| Cost of Sales | 996,701 | 873,861 | 476,610 | ||||||||
| Gross profit | 49,963 | 58,293 | 143,898 | ||||||||
| Research and development expenses | 2,338,221 | 2,143,353 | 636,801 | ||||||||
| Selling and marketing expenses | 1,618,187 | 1,081,003 | 487,904 | ||||||||
| General and administrative expenses | 3,640,967 | 2,400,000 | 1,472,872 | ||||||||
| Initial public offering expenses | 2I | — | — | 345,925 | |||||||
| Operating loss | 7,547,412 | 5,566,063 | 2,799,604 | ||||||||
| Change in fair value of convertible notes | 8 | — | — | 504,976 | |||||||
| Change in fair value of derivative warrant liabilities | 13A | (1,918,203 | ) | 5,688,891 | 277,600 | ||||||
| Issuance expenses attributable to derivate warrant liability | 10B | — | — | 247,129 | |||||||
| Interest expenses on related party loan | 15 | — | — | 152,745 | |||||||
| Other finance income, net | (217,046 | ) | (200,724 | ) | (210,675 | ) | |||||
| Net loss and comprehensive loss | 5,412,163 | 11,054,230 | 3,771,379 | ||||||||
| Net loss per ordinary share, basic and diluted | 0.31 | 0.99 | 0.77 | ||||||||
| Weighted-average number of ordinary shares outstanding, basic and diluted (*) | 17,473,499 | 11,129,978 | 4,891,071 | ||||||||
STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY (DEFICIT) (US dollars) | |||||||||||||||
| Ordinary shares | Additional | ||||||||||||||
| Number of shares | Amount | paid-in Capital | Accumulated Losses | Total | |||||||||||
| U.S. dollars | |||||||||||||||
| BALANCE AS OF | 3,597,442 | 21,456 | 12,988,292 | (14,651,678 | ) | (1,641,930 | ) | ||||||||
| Stock based compensation | — | — | 490,015 | — | 490,015 | ||||||||||
| Conversion of convertible note into ordinary shares | 504,976 | 2,734 | 2,017,170 | — | 2,019,904 | ||||||||||
| Issuance of ordinary shares and warrants upon initial public offering, net of issuance costs | 1,950,000 | 10,561 | 5,919,064 | — | 5,929,625 | ||||||||||
| Issuance of ordinary shares, pre-funded warrants, and warrants upon private placement, net of issuance costs (*) | 4,021,538 | 21,476 | 3,045,180 | — | 3,066,656 | ||||||||||
| Benefit to the Company by an equity holder with respect to funding transactions | — | — | 12,167 | — | 12,167 | ||||||||||
| Comprehensive loss | — | — | — | (3,771,379 | ) | (3,771,379 | ) | ||||||||
| BALANCE AS OF | 10,073,956 | 56,227 | 24,471,888 | (18,423,057 | ) | 6,105,058 | |||||||||
| Stock based compensation | — | — | 75,357 | — | 75,357 | ||||||||||
| Exercise of pre-funded warrants and consultants warrants (*) | 1,088,590 | 5,792 | (5,792 | ) | — | — | |||||||||
| Exercise of warrants A | 1,654,546 | 10,042 | 4,552,132 | — | 4,562,174 | ||||||||||
| Comprehensive loss | (11,054,230 | ) | (11,054,230 | ) | |||||||||||
| BALANCE AS OF | 12,817,092 | 72,061 | 29,093,585 | (29,477,287 | ) | (311,641 | ) | ||||||||
| Issuance of ordinary shares and pre-funded warrants, net of issuance costs - | 2,818,182 | 15,762 | 2,516,733 | 2,532,495 | |||||||||||
| Issuance of ordinary shares and pre-funded warrants, net of issuance costs - | 2,000,001 | 11,748 | 2,009,749 | 2,021,497 | |||||||||||
| Stock based compensation | 1,233,263 | 1,233,263 | |||||||||||||
| Issuance of shares upon restricted share units vesting | 886,398 | 5,244 | (5,244 | ) | — | ||||||||||
| Exercise of series A warrants (Note 10) | 1,144,357 | 6,348 | 3,086,862 | 3,093,210 | |||||||||||
| Comprehensive loss | (5,412,163 | ) | (5,412,163 | ) | |||||||||||
| BALANCE AS OF | 19,666,030 | 111,163 | 37,934,948 | (34,889,450 | ) | 3,156,661 | |||||||||
| (*) Includes shares issued following a cashless exercise | |||||||||||||||
STATEMENTS OF CASH FLOWS (US dollars) | ||||||||
| Year ended | ||||||||
| 2025 | 2024 | 2023 | ||||||
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||||
| Net loss | (5,412,163 | ) | (11,054,230 | ) | (3,771,379 | ) | ||
| Adjustments required to reconcile net loss to net cash used in operating activities: | ||||||||
| Depreciation | 29,174 | 22,814 | 17,087 | |||||
| Loss on disposal of property and equipment | 312 | |||||||
| Stock based compensation | 1,233,263 | 75,357 | 14,815 | |||||
| Interest expenses with respect to funding from related party | — | — | 112,373 | |||||
| Change in fair value of convertible loan | — | — | 504,976 | |||||
| Changes in fair value of derivative liabilities | (1,918,203 | ) | 5,688,891 | 277,600 | ||||
| Issuance expenses attributable to derivative warrant liabilities | — | — | 247,129 | |||||
| Inventory write-down | 194,344 | 114,617 | 33,360 | |||||
| Finance expenses | 34,371 | 689 | 583 | |||||
| Loss (gain) from exchange differences on cash and equivalents | (12,238 | ) | 31,579 | — | ||||
| Changes in operating assets and liabilities: | ||||||||
| Trade receivables, net | (70,930 | ) | (92,188 | ) | (161,689 | ) | ||
| Other current assets | 138,909 | 229,641 | (472,020 | ) | ||||
| Prepaid expenses | 21,180 | (33,333 | ) | |||||
| Inventories | (4,631 | ) | (244,343 | ) | 6,995 | |||
| Operating lease right-of-use asset | 179,323 | 135,266 | 48,766 | |||||
| Trade payables | (67,756 | ) | 127,565 | 9,422 | ||||
| Operating lease liabilities | (181,624 | ) | (134,681 | ) | (45,911 | ) | ||
| Other current liabilities | 32,617 | 243,134 | (83,785 | ) | ||||
| Net cash used in operating activities | (5,804,052 | ) | (4,889,222 | ) | (2,938,300 | ) | ||
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||||||||
| Change in restricted deposit | (12,720 | ) | (68,001 | ) | ||||
| Purchase of property and equipment | (27,804 | ) | (80,738 | ) | (25,757 | ) | ||
| Investment in short term deposits | (2,000,000 | ) | ||||||
| Net cash used in investing activities | (2,040,524 | ) | (148,739 | ) | (25,757 | ) | ||
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||||
| Proceeds from exercise of series A warrants (Note 10b) | 1,258,793 | 1,820,001 | ||||||
| Issuance of ordinary shares in initial public offering, net of issuance costs (Note 10c) | — | — | 6,695,957 | |||||
| Issuance of ordinary shares, pre-funded warrants and warrants in private placement, net of issuance costs (Note 10f and 10g) | 4,553,992 | — | 4,106,699 | |||||
| Receipt of loan from related party | — | — | 245,000 | |||||
| Repayment of loan from related party | — | — | (745,000 | ) | ||||
| Net cash provided by financing activities | 5,812,785 | 1,820,001 | 10,302,656 | |||||
Source: